Other Clinical Trial - Using the Prevent-Teach-Reinforce Model to Reduce

Status Completed

Clinical Trial Summary

Children with autism spectrum disorders often engage in problem behaviors such as self-injury, destruction, aggression, and stereotypy. Prior research has clearly shown that these problem behaviors may interfere with learning, daily functioning, and social participation. As such, engaging in problem behaviors has a negative impact on the health and quality of life of children with autism spectrum disorders and their families. One promising solution to reduce problem behaviors in this population is the Prevent-Teach-Reinforce (PTR) model, which relies on the evidence-based practices of positive behavior support. Although the use of PTR has been gaining considerably support in schools, the model has never been evaluated as part of a rigorous large-scale study using parents as interventionists. Thus, the purpose of the project is to conduct an assessment of the effectiveness of a home-based version of the PTR model in reducing problem behaviors in children with autism spectrum disorders and in improving families' quality of life. Our hypotheses are that implementing the PTR will (a) produce larger reductions in problem behaviors than participating in an individual parent training session, (b) increase engagement in prosocial behaviors, (c) decrease parental stress, and (c) improve the quality of life of the family. The results of the study will allow an examination of whether PTR is an effective and acceptable model to reduce problem behaviors at home in this population. Given that problem behaviors incur high societal costs when they persist into adolescence and adulthood, the study may potentially lead to large cost reductions in the treatment of difficulties associated with autism spectrum disorders. By reducing engagement in problem behaviors, the implementation of the model may also promote and facilitate the social participation as well as improve the quality of life and health of children with autism spectrum disorders and their families.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02153203
Study type	Interventional
Source	Université de Montréal
Contact
Status	Completed
Phase	N/A
Start date	October 2014
Completion date	September 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03222375` - SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism	N/A
Completed	`NCT01233414` - Randomized Trial of Parent Training for Young Children With Autism	N/A
Completed	`NCT00926471` - Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders	Phase 1
Withdrawn	`NCT00376194` - Mercury Chelation to Treat Autism	Phase 2
Completed	`NCT02301195` - Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder	N/A
Completed	`NCT00453180` - A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders	Phase 2
Completed	`NCT04475848` - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants	Phase 1
Terminated	`NCT01517126` - Assessing Suicide Risk in Adolescents With Developmental Delays
Completed	`NCT00080145` - RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders	N/A
Completed	`NCT00166595` - Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)	Phase 1/Phase 2
Completed	`NCT02124720` - Using Mobile Technology to Reduce Stereotypy	N/A
Completed	`NCT01731119` - Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents	Phase 2
Completed	`NCT00147394` - Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)	Phase 1
Completed	`NCT01921244` - Shared Decision Making to Improve Care and Outcomes for Children With Autism	N/A
Completed	`NCT05688319` - Effect of Problem-Solving Training	N/A
Terminated	`NCT00445471` - A Prospective Study Comparing the Mifne Approach of Treating Childhood Autism With Routine Standard Treatment	N/A
Active, not recruiting	`NCT00110708` - Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms